6-叔丁氧基吡啶-3-胺 | 58155-80-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-叔丁氧基吡啶-3-胺
• 英文名称: 6-tert-butoxypyridin-3-amine
• 英文别名: 2-tert.butoxy-5-aminopyridine；5-Amino-2-tert-butoxypyridine；6-(tert-Butoxy)pyridin-3-amine；6-[(2-methylpropan-2-yl)oxy]pyridin-3-amine
• CAS: 58155-80-9
• 化学式: C₉H₁₄N₂O
• 分子量: 166.223
• InChiKey: HRLHJWKMOMDDND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-叔丁氧基吡啶-3-胺 、 (-)-6-methylergolin-8-one 在 钯 作用下， 生成 6-methyl-8-(2-tert.butoxy-5-pyridylamino)ergoline
  参考文献：
  名称：

  3-Pyridylamine substituted ergolines

  摘要：

  这项发明提供了新的化合物，其化学式为I，##STR1## 其中R是3-吡啶基或3-吡啶基单烷基或多取代物，通过LOWER ALKYL，LOWER ALKOXY，LOWER ALKYLTHIO，PHENOXY，HALOGEN，HYDROXY或GROUP ##STR2## 进行取代，其中R.sub.1和R.sub.2各自独立地为氢或低烷基。这些化合物可用作催乳素分泌抑制剂，用于治疗泌乳素过多症。

  公开号：

  US04004011A1
• 作为产物：
  描述：

  2-[(2-甲基-2-丙基)氧基]-5-硝基吡啶 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 以88%的产率得到6-叔丁氧基吡啶-3-胺
  参考文献：
  名称：

  An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer

  摘要：

  A number of indole-3-glyoxylamides have previously been reported as tubulin polymerization inhibitors, although none has yet been successfully developed clinically. We report here a new series of related compounds, modified according to a strategy of reducing aromatic ring count and introducing a greater degree of saturation, which retain potent tubulin polymerization activity but with a distinct SAR from previously documented libraries. A subset of active compounds from the reported series is shown to interact with tubulin at the colchicine binding site, disrupt the cellular microtubule network, and exert a cytotoxic effect against multiple cancer cell lines. Two compounds demonstrated significant tumor growth inhibition in a mouse xenograft model of head and neck cancer, a type of the disease which often proves resistant to chemotherapy, supporting further development of the current series as potential new therapeutics.

  DOI：

  10.1021/acs.jmedchem.5b01312

文献信息

• 3,4-DIHYDROBENZOXAZINE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VRI) ACTIVITY
  申请人：Koga Yoshihisa

  公开号：US20070149517A1

  公开（公告）日：2007-06-28

  A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR 3 ; R 1 is a hydrogen atom or a halogen atom; R 2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and R 3 is a halogen atom. However, R 1 is a halogen atom when X is CR 3 ). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc.

  本发明的3,4-二氢苯并噁嗪化合物由以下式[1]表示（其中X为氮原子或CR3; R1为氢原子或卤素原子; R2为C1-6烷氧基，可以被同种或不同的1至5个卤素原子和羟基取代; R3为卤素原子。但是，当X为CR3时，R1为卤素原子）。该化合物对于治疗涉及vanilloid受体亚型1（VR1）活性的疾病，如疼痛等，具有有效性。
• 3,4-DIHYDROBENZOXAZINE COMPOUND AND INHIBITOR OF VANILLOID RECEPTOR TYPE 1 (VR1) ACTIVITY
  申请人：Japan Tobacco Inc.

  公开号：EP1967519A1

  公开（公告）日：2008-09-10

  A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR3; R1 is a hydrogen atom or a halogen atom; R2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and R3 is a halogen atom. However, R1 is a halogen atom when X is CR3). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc.

  本发明的 3,4-二氢苯并恶嗪化合物由下式[1]表示（其中 X 是氮原子或 CR3；R1 是氢原子或卤素原子；R2 是 C1-6 烷氧基，可被选自卤素原子和羟基的相同或不同的 1 至 5 个取代基取代；R3 是卤素原子）。然而，当 X 为 CR3 时，R1 为卤原子。）该化合物可有效治疗涉及类香草素受体亚型 1（VR1）活性的疾病，如疼痛等。
• US4004011A
  申请人：——

  公开号：US4004011A

  公开（公告）日：1977-01-18
• US7906508B2
  申请人：——

  公开号：US7906508B2

  公开（公告）日：2011-03-15
• An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer
  作者：Helen E. Colley、Munitta Muthana、Sarah J. Danson、Lucinda V. Jackson、Matthew L. Brett、Joanne Harrison、Sean F. Coole、Daniel P. Mason、Luke R. Jennings、Melanie Wong、Vamshi Tulasi、Dennis Norman、Peter M. Lockey、Lynne Williams、Alexander G. Dossetter、Edward J. Griffen、Mark J. Thompson

  DOI：10.1021/acs.jmedchem.5b01312

  日期：2015.12.10

  A number of indole-3-glyoxylamides have previously been reported as tubulin polymerization inhibitors, although none has yet been successfully developed clinically. We report here a new series of related compounds, modified according to a strategy of reducing aromatic ring count and introducing a greater degree of saturation, which retain potent tubulin polymerization activity but with a distinct SAR from previously documented libraries. A subset of active compounds from the reported series is shown to interact with tubulin at the colchicine binding site, disrupt the cellular microtubule network, and exert a cytotoxic effect against multiple cancer cell lines. Two compounds demonstrated significant tumor growth inhibition in a mouse xenograft model of head and neck cancer, a type of the disease which often proves resistant to chemotherapy, supporting further development of the current series as potential new therapeutics.